Division of Abdominal Tumor, Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan, China.
Front Immunol. 2024 Feb 13;15:1326556. doi: 10.3389/fimmu.2024.1326556. eCollection 2024.
Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at an advanced stage, presenting limited therapeutic options and a grim prognosis due to its aggressive nature. Despite ongoing exploration of various combination therapies, a standardized treatment approach after the first-line treatment progress remains elusive. This report details the cases of two patients with unresectable advanced PDAC who underwent distinct conversion treatment regimens involving immune checkpoint inhibitors (ICIs). Remarkably, both patients became eligible for surgery following different anti-PD-1 antibody-based conversion therapies, ultimately achieving R0 resection. In essence, our findings highlight the efficacy of the anti-PD-1 antibody combined with a tyrosine kinase inhibitor (TKI) regimen and chemotherapy alongside anti-PD-1 antibody as viable conversion therapies for preoperative advanced PDAC. Tumor immune microenvironment (TIME) analysis underscores the intratumoral and intertumoral heterogeneity observed in the postoperative immune landscape of surgical specimens. This insight contributes to a deeper understanding of the potential benefits of these conversion therapies in addressing the challenging landscape of advanced PDAC.
胰腺导管腺癌（PDAC）通常在晚期诊断，由于其侵袭性，治疗选择有限，预后较差。尽管正在探索各种联合治疗方法，但在一线治疗进展后，仍缺乏标准化的治疗方法。本报告详细介绍了两例不可切除的晚期 PDAC 患者的病例，他们接受了不同的免疫检查点抑制剂（ICI）转化治疗方案。值得注意的是，两名患者在不同的抗 PD-1 抗体转化治疗后均符合手术条件，最终实现了 RO 切除。本质上，我们的发现强调了抗 PD-1 抗体联合酪氨酸激酶抑制剂（TKI）方案和化疗联合抗 PD-1 抗体作为术前晚期 PDAC 可行转化治疗的疗效。肿瘤免疫微环境（TIME）分析强调了手术标本中术后免疫景观中观察到的肿瘤内和肿瘤间异质性。这一见解有助于更深入地了解这些转化治疗在解决晚期 PDAC 挑战性景观方面的潜在益处。
